Director/PDMR Shareholding

 
TIDMNVOB 
 
In accordance with Section 28a of the Danish Securities Trading Act, Novo 
Nordisk is required on a daily basis to publish trading in Novo Nordisk shares 
by the company's board members, executives and their associated persons as 
reported by those persons to Novo Nordisk. 
 
Please find below a statement of such trading in shares issued by Novo Nordisk. 
 
+--------------------------------+--------------------------------+ 
|Name                            |Kurt Anker Nielsen              | 
+--------------------------------+--------------------------------+ 
|Reason for reporting            |Member of the Board of Directors| 
+--------------------------------+--------------------------------+ 
|Financial instrument and ID code|Novo Nordisk B DK006010261      | 
+--------------------------------+--------------------------------+ 
|Type of transaction             |Sale of shares                  | 
+--------------------------------+--------------------------------+ 
|Date of transaction             |3 February 2010                 | 
+--------------------------------+--------------------------------+ 
|Place of transaction            |NASDAQ OMX Copenhagen           | 
+--------------------------------+--------------------------------+ 
|Volume of transaction           |2,000 shares                    | 
+--------------------------------+--------------------------------+ 
|Total value of transaction      |DKK 755,400                     | 
+--------------------------------+--------------------------------+ 
 
 
Definitions and background information: 
 
Publication 
 
Publication shall take place the day after Novo Nordisk receives sufficient 
information on the trading. Publication is only required when the total amount 
of transactions of a specific board member/executive and his/her associated 
persons in any one calendar year has reached 5,000 euros. 
 
Board members and executives are members of the Board of Directors and Executive 
Management, respectively, of Novo Nordisk A/S. Associated persons are defined as 
the following persons associated to a board member/executive: 1) spouse or 
cohabitant, 2) children under the age of 18 years, 3) relatives defined as 
brothers, sisters, parents, grandparents etc, children, grandchildren etc who 
have shared the same household with a board member/executive for at least one 
year, and 4) any legal person, including a company, a foundation or a 
partnership, which is controlled directly or indirectly by a board 
member/executive and/or a person mentioned in 1)-3), or to which a board 
member/executive and/or a person mentioned in 1)-3) has managerial 
responsibilities or economic interests substantially equivalent to the legal 
person. 
 
What is trading/transaction? 
Trading is any kind of transaction, including shares purchased or otherwise 
acquired, shares sold or otherwise disposed, gifts, mortgages and grants and 
exercise of options, but not heritage. 
 
Financial instrument includes shares listed on the NASDAQOMX Copenhagen and 
London Stock Exchange as well as ADRs listed on New York Stock Exchange, except 
for ADRs held in 401(k) retirement plan by US-based employees. The ID code is 
the code (ISIN DK006010261) of the Novo Nordisk share on the NASDAQ OMX 
Copenhagen, the code (NVOB) on London Stock Exchange or the code (NVO) on New 
York Stock Exchange. 
 
The volume of transaction is the number of shares (of DKK 1 nominal value) or 
other financial instruments traded. The transaction value is the number of 
shares traded multiplied by the transaction price. The exchange rate of the 
Danish Central Bank (Nationalbanken) on the date of transaction is used for 
calculating the transaction value in DKK in case of shares traded on London 
Stock Exchange and ADRs listed on New York Stock Exchange. 
 
Novo Nordisk is a healthcare company and a world leader in diabetes care. In 
addition, Novo Nordisk has a leading position within areas such as haemostasis 
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk 
manufactures and markets pharmaceutical products and services that make a 
significant difference to patients, the medical profession and society. With 
headquarters in Denmark, Novo Nordisk employs over 29,300 employees in 81 
countries, and markets its products in 179 countries. Novo Nordisk's B shares 
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed 
on the New York Stock Exchange under the symbol 'NVO'. For more information, 
visit novonordisk.com. 
 
For further information please contact: 
 
 
 Media:                                  Investors: 
 
 
 Outside North America:                  Outside North America: 
 
 Mette Kruse Danielsen                   Klaus Bülow Davidsen 
 
 Tel: [phone]                    Tel: [phone] 
 E-mail:[e-mail]              E-mail:[e-mail] 
 <mailto:[e-mail]>            <mailto:[e-mail]> 
 
                                         Kasper Roseeuw Poulsen 
 
                                         Tel: [phone] 
 
                                         E-mail:[e-mail] 
                                         <mailto:[e-mail]> 
 
 
 
 In North America:                       In North America 
 
 Sean Clements                           Hans Rommer 
 
 Tel: [phone]                  Tel: [phone] 
 
 E-mail:[e-mail]             E-mail:[e-mail] 
 <mailto:[e-mail]>           <mailto:[e-mail]> 
 
 
Company Announcement no 6 /2010 
 
 
 
[HUG#1380778] 
 
 
 
 
 
    Company Announcement no 6 2010: http://hugin.info/2013/R/1380778/340236.pdf